The pharmacokinetics of Biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: The Stealth PK Study

European Journal of Clinical Pharmacology

Volumn 67, Issue 4, 2011, Pages 389-398

  Ostojic, Miodrag C ^a   Perisic, Zoran ^b   Sagic, Dragan ^c   Jung, Robert ^d   Zhang, Yan Ling ^e   Bendrick Peart, Jamie ^f   Betts, Ronald ^g   Christians, Uwe ^e  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b Clinical Centre Nis   (Serbia)

^c Institute for Cardiovascular Disease Dedinje   (Serbia)

^d Institute for Cardiovascular Disease   (Serbia)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f Eurofins Medinet Inc   (Germany)

^g Biosensors International USA   (United States)

Author keywords

Biolimus A9; Coronary muscle cell proliferation inhibition; Drug eluting coronary stents; Pharmacokinetics; Safety; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLIMUS A9; CLOPIDOGREL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EVEROLIMUS; RAPAMYCIN; TICLOPIDINE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG STRUCTURE; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; STENT THROMBOSIS; TANDEM MASS SPECTROMETRY; TREATMENT DURATION;

AGED; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; SIROLIMUS; TREATMENT OUTCOME;

EID: 79954579260     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0895-1     Document Type: Article

References (30)

1. MM El-Omar C Dangas I Iakovou R Mehran 2001 Update on in-stent restenosis Curr Interv Cardiol Rep 3 296 305 11696295
2. HC Lowe SN Oesterle LM Khachigian 2002 Coronary in-stent restenosis: current status and future strategies J Am Coll Cardiol 39 183 103 11788206 10.1016/S0735-1097(01)01742-9 (Pubitemid 34084620)
3. RR Anis KR Karsch M Oberhoff 2006 An update on clinical and pharmacological aspects of drug-eluting stents Cardiovasc Hematol Disord Drug Targets 6 245 255 17378770 1:CAS:528:DC%2BD28Xht1SmsrvJ (Pubitemid 44890587)
4. L Slavin A Chhabra JM Tobis 2007 Drug-eluting stents: preventing restenosis Cardiol Rev 15 1 12 17172878 10.1097/01.crd.0000200844.16899.fc (Pubitemid 46005943)
5. NN Kipshidze MV Tsapenko MB Leon GW Stone JW Moses 2005 Update on drug-eluting stents Expert Rev Cardiovasc Ther 3 953 968 16181039 10.1586/14779072.3.5.953 1:CAS:528:DC%2BD2MXhtFOjsL7M (Pubitemid 41448208)
6. MC Morice PW Serruys JE Sousa for the RAVEL study group 2002 A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization N Engl J Med 346 1773 1780 12050336 10.1056/NEJMoa012843 1:CAS:528:DC%2BD38Xkt1Olsbw%3D (Pubitemid 34586912)
7. JW Moses MB Leon JJ Popma PJ Fitzgerald DR Holmes C O'Shaughnessy RP Caputo DJ Kereiakes DO Williams PS Teirstein JL Jaeger RE Kuntz SIRIUS Investigators 2003 Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 1315 1323 14523139 10.1056/NEJMoa035071 1:CAS:528:DC%2BD3sXnvVGitrc%3D (Pubitemid 37186209)
8. EJ Smith AK Jain MT Rothman 2006 New developments in coronary stent technology J Interv Cardiol 19 493 499 17107363 10.1111/j.1540-8183.2006.00199.x (Pubitemid 44722240)
9. E Grube L Buellesfeld 2006 BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease Expert Rev Med Dev 3 731 741 10.1586/17434440.3.6.731 1:CAS:528:DC%2BD2sXhvFGltro%3D (Pubitemid 46017613)
10. S Huang MA Bjornsti PJ Houghton 2003 Rapamycins: mechanism of action and cellular resistance Cancer Biol Ther 2 222 232 12878853 1:CAS:528: DC%2BD3sXosFCgs7o%3D
11. BD Kahan 2001 Sirolimus; a comprehensive review Expert Opin Pharmacother 2 1903 1917 11825325 10.1517/14656566.2.11.1903 1:CAS:528:DC%2BD3MXptVOjurc%3D (Pubitemid 33069483)
12. SN Sehgal 2003 Sirolimus: its discovery, biological properties, and mechanism of action Transplant Proc 35 7S 14S 12742462 10.1016/S0041-1345(03) 00211-2 1:CAS:528:DC%2BD3sXksFGqt78%3D (Pubitemid 36547910)
13. RA Costa AJ Lansky A Abizaid R Müeller Y Tsuchiya K Mori E Cristea MB Leon JE Sousa T Schmidt KE Hauptmann E Grube 2006 Angiographic results of the first human experience with the Biolimus A9 drug-eluting stent for de novo coronary lesions Am J Cardiol 98 443 446 16893694 10.1016/j.amjcard.2006.02.051 1:CAS:528:DC%2BD28XotFKisLk%3D (Pubitemid 44177576)
14. P Agostoni S Verheye 2007 Bifurcation stenting with a dedicated biolimus-eluting stent: X-ray visual enhancement of the final angiographic result with "stentboost subtract" Catheter Cardiovasc Interv 70 233 236 17377996 10.1002/ccd.21096 (Pubitemid 47206034)
15. S Windecker PW Serruys S Wandel P Buszman S Trznadel A Linke K Lenk T Ischinger V Klauss F Eberli R Corti W Wijns MC Morice C di Mario S Davies RJ van Geuns P Eerdmans GA van Es B Meier P Jüni 2008 Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial Lancet 372 1163 1173 18765162 10.1016/S0140-6736(08)61244-1 1:CAS:528: DC%2BD1cXhtFOgtLvN
16. P Barlis E Regar PW Serruys K Dimopoulos WJ van der Giessen RJ van Geuns G Ferrante S Wandel S Windecker GA van Es P Eerdmans P Jüni C di Mario 2010 An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study Eur Heart J 31 165 176 19889649 10.1093/eurheartj/ehp480 1:CAS:528:DC%2BC3cXntlKksQ%3D%3D
17. JJ Wykrzykowska PW Serruys Y Onuma T de Vries GA van Es P Buszman A Linke T Ischinger V Klauss R Corti F Eberli W Wijns MC Morice C di Mario RJ van Geuns P Juni S Windecker 2009 Impact of vessel size on angiographic and clinical outcomes of revascularization with biolimus-eluting stent with biodegradable polymer and sirolimus-eluting stent with durable polymer the LEADERS trial substudy J Am Coll Cardiol Cardiovasc Interv 2 861 870
18. JJ Wykrzykowska L Räber T de Vries M Bressers P Buszman A Linke T Ischinger V Klauss F Eberli R Corti W Wijns MC Morice C di Mario E Regar P Jüni S Windecker PW Serruys 2009 Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions: results from the LEADERS multicentre trial substudy EuroIntervention 5 310 317 19736154 10.4244/V5I3A49
19. GW Vetrovec D Rizik C Williard D Snead V Piotrovski G Kopia 2006 Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx Velocity stent in patients with de novo coronary lesions Catheter Cardiovasc Interv 67 32 37 16342216 10.1002/ccd.20565 (Pubitemid 43062605)
20. S Verheye P Agostoni CL Dubois J Dens J Ormiston S Worthley B Trauthen T Hasegawa BK Koo PJ Fitzgerald R Mehran AJ Lansky 2009 9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study J Am Coll Cardiol 53 1031 1039 19298915 10.1016/j.jacc.2008. 12.012
21. E Grube H Sievert KE Hauptmann R Mueller U Gerckens L Buellesfeld J Ako T Shimohama M Costa P Fitzgerald 2008 Novel drug eluting stent system for customised treatment of coronary lesions: CUSTOM I feasibility trial 24 month results EuroIntervention 4 71 76 19112782 10.4244/EIJV4I1A13
22. PR Stella R Mueller G Pavlakis B De Bruyne K Hauptmann MC Morice B Chevalier J Fajadet H Sievert E Grube Custom-II Investigators 2008 One year results of a new in situ length-adjustable stent platform with a biodegradable biolimus A9 eluting polymer: results of the CUSTOM-II trial EuroIntervention 4 200 207 19110784 10.4244/EIJV4I2A37
23. M Ostojic D Sagic R Jung YL Zhang M Nedeljkovic L Mangovski S Stojkovic D Debeljacki M Colic B Beleslin B Milosavljevic D Orlic D Topic N Karanovic D Paunovic U Christians NOBORIPK Investigators 2008 The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study Catheter Cardiovasc Interv 72 901 908 19016466 10.1002/ccd.21775
24. MI Hamilos M Ostojic B Beleslin D Sagic L Mangovski S Stojkovic M Nedeljkovic D Orlic B Milosavljevic D Topic N Karanovic W Wijns NOBORICORE Investigators 2008 Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion J Am Coll Cardiol 51 2123 2129 18510958 10.1016/j.jacc.2007.12.059 1:CAS:528:DC%2BD1cXms1WktLk%3D (Pubitemid 351721001)
25. C Clavijo T Strom V Moll R Betts YL Zhang U Christians J Bendrick-Peart 2009 Development and validation of a semi-automated assay for the highly sensitive quantification of Biolimus A9 in human whole blood using high performance liquid chromatography-tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 877 3506 3514 19762292 10.1016/j.jchromb.2009.08.020 1:CAS:528:DC%2BD1MXht1GksLjM
26. Steudel W, Dingmann C, Zhang YL, Bendrick-Peart J, Shulze J, Betts R, Christians U (2010) A randomized, double-blind, placebo-controlled, single intravenous, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of the novel coronary smooth muscle cell proliferation inhibitor Biolimus A9 in healthy individuals. J Clin Pharmacol (in press)
27. K Mahalati BD Kahan 2001 Clinical pharmacokinetics of sirolimus Clin Pharmacokinet 40 573 585 11523724 10.2165/00003088-200140080-00002 1:CAS:528:DC%2BD3MXmsl2gsLc%3D (Pubitemid 32758580)
28. GI Kirchner I Meier-Wiedenbach MP Manns 2004 Clinical pharmacokinetics of everolimus Clin Pharmacokinet 43 83 95 14748618 10.2165/00003088-200443020- 00002 1:CAS:528:DC%2BD2cXisFGkurY%3D (Pubitemid 38283132)
29. U Christians W Jacobsen N Serkova LZ Benet C Vidal KF Sewing MP Mann GI Kirchner 2000 Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants J Chromatogr B 748 41 53 10.1016/S0378-4347(00)00380-7 1:CAS:528:DC%2BD3cXotF2ltLk%3D
30. YL Zhang J Bendrick-Peart T Strom M Haschke U Christians 2005 Development and validation of a high-throughput assay for quantification of the proliferation inhibitor ABT-578 using LC/LC-MS/MS in blood and tissue samples Ther Drug Monit 27 770 778 16306853 10.1097/01.ftd.0000185766.52126.bd 1:CAS:528:DC%2BD2MXht1Cit7vI (Pubitemid 44391733)